Q&A With Scott Wasserman From Amgen: Repatha's Approval Marks New Chapter in Cholesterol Management
PCSK9 inhibitors have been the focus of the cardiology community and with the approval of two medications in the past few months these drugs could soon make their way to a large number of patients needing help managing their cholesterol levels using more than just statins.
PCSK9 inhibitors have been the focus of the cardiology community and with the approval of two medications in the past few months these drugs could soon make their way to a large number of patients needing help managing their cholesterol levels using more than just statins.
Scott Wasserman, MD, Vice President of Global Development at Amgen discussed the latest medication to be approved in the field during the European Society of Cardiology's annual conference in London.
While there has been mostly good news about the newly developed PCSK9 inhibitors there have also been questions raised about the therapy as well. What the future holds for cholesterol management is also a question being debated in the field.
